Literature DB >> 6323620

A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice.

H J Field, J R Anderson, S Efstathiou.   

Abstract

Mice with established herpes encephalitis were used to compare the effects of chemotherapy using three different nucleoside analogues. Encephalitis was produced by intranasal inoculation of a type 1 strain of herpes simplex virus. Without chemotherapy all mice died within 5 to 7 days of inoculation. Oral acyclovir (ACV) was a successful preventative measure if commenced within 2 days of inoculation but much less effective if the onset of treatment was further delayed. From the third day, when central nervous system infection had definitely become established, ACV only reduced mortality if given intraperitoneally (i.p.) at regular 6-hourly intervals. Comparison with bromovinyldeoxyuridine (BVdU) and the new nucleoside analogue dihydroxypropoxymethylguanine (DHPG) using the same 6-hourly i.p. regimen revealed that BVdU was poorly effective, despite better activity in vitro, whereas DHPG was the most successful. Virus was rapidly eradicated from all parts of the brain by DHPG therapy, and by day 10, no infectious virus remained in the brains of treated mice, no virus antigens were observed and no trace of virus DNA could be detected in neural tissues by Southern blotting.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323620     DOI: 10.1099/0022-1317-65-4-707

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  Effect of antiviral agents on replication of herpes simplex virus type 1 in brain cultures.

Authors:  L Pulliam; H S Panitch; J R Baringer; R D Dix
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

Authors:  Ulrich A K Betz; Rüdiger Fischer; Gerald Kleymann; Martin Hendrix; Helga Rübsamen-Waigmann
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  A novel oral vehicle for poorly soluble HSV-helicase inhibitors: PK/PD validations.

Authors:  Jianmin Duan; Francine Liard; William Paris; Michelle Lambert
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

Review 5.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

6.  Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice.

Authors:  H Yang; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

7.  Brain resistance to HSV-1 encephalitis in a mouse model.

Authors:  G Altavilla; A Calistri; A Cavaggioni; M Favero; C Mucignat-Caretta; G Palù
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

8.  Neural Progenitor Cells Expressing Herpes Simplex Virus-Thymidine Kinase for Ablation Have Differential Chemosensitivity to Brivudine and Ganciclovir.

Authors:  Zijian Lou; Alexander Post; Christopher E Rodgers; Mahmood Chamankhah; James Hong; Christopher S Ahuja; Mohamad Khazaei; Michael G Fehlings
Journal:  Front Cell Neurosci       Date:  2021-12-06       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.